HC Wainwright started coverage on shares of Kindred Biosciences, Inc. (NASDAQ:KIN) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $9.50 price objective on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research cut shares of Kindred Biosciences from a buy rating to a hold rating in a report on Wednesday, October 11th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $9.54.

Kindred Biosciences (KIN) opened at $7.45 on Friday. Kindred Biosciences has a one year low of $3.90 and a one year high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. equities research analysts forecast that Kindred Biosciences will post -1.14 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2017/11/21/kindred-biosciences-inc-kin-receives-new-coverage-from-analysts-at-hc-wainwright.html.

Several large investors have recently bought and sold shares of the company. Nationwide Fund Advisors purchased a new stake in Kindred Biosciences in the second quarter worth approximately $100,000. JPMorgan Chase & Co. purchased a new stake in Kindred Biosciences in the second quarter worth approximately $119,000. Trexquant Investment LP purchased a new stake in Kindred Biosciences in the second quarter worth approximately $120,000. SG Americas Securities LLC purchased a new stake in Kindred Biosciences in the third quarter worth approximately $123,000. Finally, OxFORD Asset Management LLP purchased a new stake in Kindred Biosciences in the second quarter worth approximately $128,000. Hedge funds and other institutional investors own 61.77% of the company’s stock.

About Kindred Biosciences

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.